Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...

Tirzepatide promoted greater weight loss in individuals with obesity than semaglutide in a clinical trial that compared the ...

Federal regulators have accepted Novo Nordisk’s application to produce a pill version of its injectable weight-loss ...

Eli Lilly and Company (NYSE:LLY) is a leading medicine company which discovers, develops, manufactures, and markets products ...

Scented candles have taken the market by storm. Known to be therapeutic, these candles are quickly making their way into our ...

Eli Lilly and Company ( NYSE: LLY) BofA Securities 2025 Health Care Conference Call May 15, 2025 11:40 AM ET Lucas Montarce - CFO Mike Czapar - SVP, IR ...

A study of two blockbuster weight-loss drugs showed that users of Eli Lilly’s Zepbound lost just over 2 inches more off their waists compared with Novo Nordisk’s rival Wegovy. Barbara ...

Hong Kong's stock market ended lower Friday with the benchmark Hang Seng Index down 0.46 percent to close at 23,345.05 ...

A blockbuster antitrust trial featuring Meta kicked off in the US last week, with CEO Mark Zuckerberg taking the stand in court to defend the tech giant’s acquisitions of Instagram and WhatsApp over a ...